James A. Schoeneck - 17 Aug 2026 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Reporting relationship: Director
Issuer ticker: CLDI
Reported as of: 17 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Aug 2026, 19:00:08 UTC
Prior SEC filing: 17 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Andrew Jackson, Attorney-in-fact

Key filing fact

James A. Schoeneck filed Form 4 for Calidi Biotherapeutics, Inc. (CLDI) on 19 Aug 2026.

Key facts

This page summarizes James A. Schoeneck's Form 4 filing for Calidi Biotherapeutics, Inc. (CLDI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 Aug 2026, 19:00.

Change

Previous filing in this sequence was filed on 17 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001420987 Primary reporting owner

Schoeneck James A

Relationship: Director
Address: C/O CALIDI BIOTHERAPEUTICS, INC., 4475 EXECUTIVE DRIVE, SUITE 200, SAN DIEGO,
Signature: /s/ Andrew Jackson, Attorney-in-fact
Signature date: 19 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLDI transaction Derivative

Non-Qualified Stock Options (right to buy)

Award

Transaction value
Shares: +5,000
Change %
Price: $0.000000^*
Shares after: 5,000
Date: 17 Aug 2026
Ownership: Direct
Underlying class: Common stock
Underlying amount: 5,000
Exercise price: $1.36
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 5,000 shares of common stock (the "Options") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan.

Footnote F2

Does not include the stock options previously granted to the Reporting Person.